$-1.09 EPS Expected for Blueprint Medicines Corporation (BPMC)

April 26, 2018 - By reb123z

Blueprint Medicines Corporation (NASDAQ:BPMC) Logo

Analysts expect Blueprint Medicines Corporation (NASDAQ:BPMC) to report $-1.09 EPS on May, 2.They anticipate $0.25 EPS change or 29.76 % from last quarter’s $-0.84 EPS. After having $-1.23 EPS previously, Blueprint Medicines Corporation’s analysts see -11.38 % EPS growth. The stock decreased 3.27% or $2.65 during the last trading session, reaching $78.33. About 215,764 shares traded. Blueprint Medicines Corporation (NASDAQ:BPMC) has risen 101.73% since April 26, 2017 and is uptrending. It has outperformed by 90.18% the S&P500.

Blueprint Medicines Corporation (NASDAQ:BPMC) Ratings Coverage

Among 7 analysts covering Blueprint Medicines (NASDAQ:BPMC), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Blueprint Medicines had 10 analyst reports since October 31, 2017 according to SRatingsIntel. JMP Securities maintained it with “Buy” rating and $10900 target in Monday, April 16 report. BTIG Research maintained the shares of BPMC in report on Monday, November 13 with “Buy” rating. The stock has “Buy” rating by Wedbush on Monday, November 6. The stock has “Buy” rating by Goldman Sachs on Monday, December 11. The firm has “Buy” rating given on Tuesday, October 31 by BTIG Research. The firm earned “Buy” rating on Monday, April 16 by Canaccord Genuity. The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) earned “Buy” rating by Canaccord Genuity on Wednesday, November 1. Wedbush maintained it with “Buy” rating and $10600 target in Monday, April 16 report. The stock has “Buy” rating by Jefferies on Friday, December 22.

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. The company has market cap of $3.42 billion. The Company’s lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It currently has negative earnings. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase and predicted NTRK resistant mutants.

Blueprint Medicines Corporation (NASDAQ:BPMC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.